These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 32211500)

  • 1. Cerebrospinal fluid neurofilament light concentration predicts brain atrophy and cognition in Alzheimer's disease.
    Dhiman K; Gupta VB; Villemagne VL; Eratne D; Graham PL; Fowler C; Bourgeat P; Li QX; Collins S; Bush AI; Rowe CC; Masters CL; Ames D; Hone E; Blennow K; Zetterberg H; Martins RN
    Alzheimers Dement (Amst); 2020; 12(1):e12005. PubMed ID: 32211500
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma Aβ42/40 ratio, p-tau181, GFAP, and NfL across the Alzheimer's disease continuum: A cross-sectional and longitudinal study in the AIBL cohort.
    Chatterjee P; Pedrini S; Doecke JD; Thota R; Villemagne VL; Doré V; Singh AK; Wang P; Rainey-Smith S; Fowler C; Taddei K; Sohrabi HR; Molloy MP; Ames D; Maruff P; Rowe CC; Masters CL; Martins RN;
    Alzheimers Dement; 2023 Apr; 19(4):1117-1134. PubMed ID: 36574591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cerebrospinal Fluid Neurofilament Light Predicts Risk of Dementia Onset in Cognitively Healthy Individuals and Rate of Cognitive Decline in Mild Cognitive Impairment: A Prospective Longitudinal Study.
    Dhiman K; Villemagne VL; Fowler C; Bourgeat P; Li QX; Collins S; Bush AI; Rowe CC; Masters CL; Ames D; Blennow K; Zetterberg H; Martins RN; Gupta V
    Biomedicines; 2022 Apr; 10(5):. PubMed ID: 35625782
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cerebrospinal fluid neurofilament light chain and total-tau as biomarkers of neurodegeneration in Alzheimer's disease and frontotemporal dementia.
    Giuffrè GM; Quaranta D; Costantini EM; Citro S; Martellacci N; De Ninno G; Vita MG; Guglielmi V; Rossini PM; Calabresi P; Marra C
    Neurobiol Dis; 2023 Oct; 186():106267. PubMed ID: 37652185
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease.
    Mattsson N; Cullen NC; Andreasson U; Zetterberg H; Blennow K
    JAMA Neurol; 2019 Jul; 76(7):791-799. PubMed ID: 31009028
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of Plasma Neurofilament Light With Neurodegeneration in Patients With Alzheimer Disease.
    Mattsson N; Andreasson U; Zetterberg H; Blennow K;
    JAMA Neurol; 2017 May; 74(5):557-566. PubMed ID: 28346578
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of CSF and plasma NfL and pNfH for Alzheimer's disease diagnosis: a memory clinic study.
    Vrillon A; Ashton NJ; Karikari TK; Götze K; Cognat E; Dumurgier J; Lilamand M; Zetterberg H; Blennow K; Paquet C
    J Neurol; 2024 Mar; 271(3):1297-1310. PubMed ID: 37950758
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel Biomarkers for Alzheimer's Disease: Plasma Neurofilament Light and Cerebrospinal Fluid.
    Abukuri DN
    Int J Alzheimers Dis; 2024; 2024():6668159. PubMed ID: 38779175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Race modifies the relationship between cognition and Alzheimer's disease cerebrospinal fluid biomarkers.
    Howell JC; Watts KD; Parker MW; Wu J; Kollhoff A; Wingo TS; Dorbin CD; Qiu D; Hu WT
    Alzheimers Res Ther; 2017 Nov; 9(1):88. PubMed ID: 29096697
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma neurofilament light and phosphorylated tau 181 as biomarkers of Alzheimer's disease pathology and clinical disease progression.
    Clark C; Lewczuk P; Kornhuber J; Richiardi J; Maréchal B; Karikari TK; Blennow K; Zetterberg H; Popp J
    Alzheimers Res Ther; 2021 Mar; 13(1):65. PubMed ID: 33766131
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of Cerebrospinal Fluid Neurofilament Light Protein With Risk of Mild Cognitive Impairment Among Individuals Without Cognitive Impairment.
    Kern S; Syrjanen JA; Blennow K; Zetterberg H; Skoog I; Waern M; Hagen CE; van Harten AC; Knopman DS; Jack CR; Petersen RC; Mielke MM
    JAMA Neurol; 2019 Feb; 76(2):187-193. PubMed ID: 30419087
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma Amyloid-β, Total Tau, and Neurofilament Light Chain Across the Alzheimer's Disease Clinical Spectrum: A Population-Based Study.
    Dong Y; Hou T; Li Y; Liu R; Cong L; Liu K; Liu C; Han X; Ren Y; Tang S; Winblad B; Blennow K; Wang Y; Du Y; Qiu C
    J Alzheimers Dis; 2023; 96(2):845-858. PubMed ID: 37899059
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum neurofilament light chain levels in patients with cognitive deficits and movement disorders: comparison of cerebrospinal and serum neurofilament light chain levels with other biomarkers.
    Novobilský R; Bartova P; Lichá K; Bar M; Stejskal D; Kusnierova P
    Front Hum Neurosci; 2023; 17():1284416. PubMed ID: 38164192
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma neurofilament light as a potential biomarker of neurodegeneration in Alzheimer's disease.
    Lewczuk P; Ermann N; Andreasson U; Schultheis C; Podhorna J; Spitzer P; Maler JM; Kornhuber J; Blennow K; Zetterberg H
    Alzheimers Res Ther; 2018 Jul; 10(1):71. PubMed ID: 30055655
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma β-amyloid, tau, neurodegeneration biomarkers and inflammatory factors of probable Alzheimer's disease dementia in Chinese individuals.
    Sun Q; Ni J; Wei M; Long S; Li T; Fan D; Lu T; Shi J; Tian J
    Front Aging Neurosci; 2022; 14():963845. PubMed ID: 36062146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma neurofilament light chain as a biomarker of Alzheimer's disease in Subjective Cognitive Decline and Mild Cognitive Impairment.
    Giacomucci G; Mazzeo S; Bagnoli S; Ingannato A; Leccese D; Berti V; Padiglioni S; Galdo G; Ferrari C; Sorbi S; Bessi V; Nacmias B
    J Neurol; 2022 Aug; 269(8):4270-4280. PubMed ID: 35288777
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Saliva Neurofilament Light Chain Is Not a Diagnostic Biomarker for Neurodegeneration in a Mixed Memory Clinic Population.
    Gleerup HS; Sanna F; Høgh P; Simrén J; Blennow K; Zetterberg H; Hasselbalch SG; Ashton NJ; Simonsen AH
    Front Aging Neurosci; 2021; 13():659898. PubMed ID: 34040512
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decreased cerebrospinal fluid neuronal pentraxin receptor is associated with PET-Aβ load and cerebrospinal fluid Aβ in a pilot study of Alzheimer's disease.
    Lim B; Fowler C; Li QX; Rowe C; Dhiman K; Gupta VB; Masters CL; Doecke JD; Martins RN; Collins S; Diamandis EP
    Neurosci Lett; 2020 Jul; 731():135078. PubMed ID: 32450185
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease.
    Mattsson N; Insel PS; Palmqvist S; Portelius E; Zetterberg H; Weiner M; Blennow K; Hansson O;
    EMBO Mol Med; 2016 Oct; 8(10):1184-1196. PubMed ID: 27534871
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Review of Fluid Biomarkers for Alzheimer's Disease: Moving from CSF to Blood.
    Blennow K
    Neurol Ther; 2017 Jul; 6(Suppl 1):15-24. PubMed ID: 28733960
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.